MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12885-026-16312-8

Медицинская библиотека · BMC cancer · 2026

Evolution of treatment patterns and survival outcomes in non-metastatic rectal cancer: a 15-year real-world single-center analysis.

Jang Jeong Yun, Lim Haesol, Ko Jiyeon, Lee Jeong Ha, Kim Yuwon, Chi Sang Ah, Yoo Gyu Sang, Park Hee Chul, Kim Nalee, Cho Yong Beom, Yu Jeong Il

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Treatment strategies for rectal adenocarcinoma have undergone substantial evolution, driven by advances in surgical techniques, radiotherapy, and systemic therapies. Nonetheless, longitudinal evidence on their real-world adoption and survival trends remains limited. This study investigated temporal trends in patient characteristics, treatment patterns, and outcomes over a 15-year period at a high-volume Korean tertiary center.

METHODS

We retrospectively evaluated 6,314 patients with non-metastatic rectal adenocarcinoma who received curative-intent treatment between 2008 and 2022. The study period was divided into five consecutive 3-year intervals to facilitate temporal comparisons.

RESULTS

The mean age at diagnosis was 59.4 years, and 62.0% of patients were male. The proportion of clinical T4 tumors increased substantially, from 7.0% to 28.0%, whereas well-differentiated histology declined over time. Minimally invasive surgery rose from 44.5% to 91.0%, driven by the growing adoption of robotic techniques. Neoadjuvant radiotherapy replaced adjuvant radiotherapy as the predominant approach, and capecitabine-based regimens became the most frequent systemic therapy. Across the entire cohort, the 5-year survival rate was 87.6%, with overall survival showing steady improvement across study periods. Relative to the general population, the standardized mortality ratio declined from 5.57 in Period 1 to 3.33 in Period 5, reflecting a measurable reduction in excess mortality. Among patients with locally advanced disease, the highest five-year survival rate was 88.4% in those treated with neoadjuvant therapy followed by surgery.

CONCLUSIONS

These findings demonstrate substantial temporal changes in multidisciplinary rectal cancer management, with improved survival observed over time, supporting the continued refinement of multidisciplinary care strategies.

Для цитирования: Jang Jeong Yun, Lim Haesol, Ko Jiyeon, Lee Jeong Ha, Kim Yuwon, Chi Sang Ah, Yoo Gyu Sang, Park Hee Chul, Kim Nalee, Cho Yong Beom, Yu Jeong Il. Evolution of treatment patterns and survival outcomes in non-metastatic rectal cancer: a 15-year real-world single-center analysis.. BMC cancer. 2026. DOI: 10.1186/s12885-026-16312-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.